Abzena plc, a technology and service provider for the development and manufacturing of biopharmaceutical products, is collaborating with Enleofen Bio to develop antibody therapeutics for the treatment of fibrotic human diseases.

Enleofen Bio discovered that inhibiting Interleukin 11 (IL11) prevents fibrosis through a wide range of pathways. They have developed various IL11 inhibitors, and their development program is now being advanced with the use of Abzena’s Composite CHO cell line technology. 

Under the partnership, Abzena will also support Enleofen Bio through the development of alternative strategies to block IL11 signaling. 

“We believe anti-IL11 therapies will transform the treatment of patients suffering from fibrosis of the lung, heart, liver, kidneys and other organs. We chose to work with Abzena because of its proven expertise in antibody engineering and cell line development.” said Stuart Cook, co-founder of Enleofen Bio.